BCLI
- Brainstorm Cell Therapeutics Inc.
()
Overview
Company Summary
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology company that focuses on the development and commercialization of innovative autologous adult stem cell therapies for neurological diseases.
The company's primary goal is to address unmet medical needs in debilitating neurological conditions, such as Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS). BCLI's approach is founded on the use of the patient's own bone marrow-derived mesenchymal stem cells (MSCs) to develop therapeutic treatments.
The company has developed a proprietary technology called NurOwn�, which involves isolating and modifying MSCs to enhance their ability to produce and deliver important neurotrophic factors (proteins that promote the growth and survival of neurons). These modified cells are then injected back into the patient's body, where they can potentially slow disease progression, improve symptoms, and promote recovery.
BCLI conducts preclinical and clinical trials to evaluate the safety, efficacy, and potential benefits of its NurOwn� therapy. The company collaborates with leading research institutions and healthcare providers to conduct these studies and gather valuable data. If successful, BCLI aims to obtain regulatory approvals and bring its stem cell therapy to market, providing a much-needed treatment option for patients suffering from neurological disorders.
In addition to its core therapeutic focus, BCLI also invests in research and development efforts to explore the applications of its stem cell technology in other neurological conditions and develops platform technologies to support its pipeline of potential treatments.
Overall, Brainstorm Cell Therapeutics Inc. focuses on developing and commercializing innovative stem cell therapies to address neurological diseases, using its proprietary NurOwn� technology, with the ultimate aim of improving patients' quality of life and potentially transforming the field of regenerative medicine.